Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants

The heparin polysaccharide nanoparticles block the interaction between heparan sulfate/S protein and inhibit the infection of both wild-type SARS-CoV-2 pseudovirus and the mutated strains through pulmonary delivery. [Figure: see text]

Detalles Bibliográficos
Autores principales: Tu, Bin, Wang, Huiyuan, An, Xinran, Qu, Jingkun, Li, Qianqian, Gao, Yanrong, Shi, Mingjie, Qiu, Hong, Huang, Yongzhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830937/
https://www.ncbi.nlm.nih.gov/pubmed/35169535
http://dx.doi.org/10.1016/j.apsb.2022.01.019
_version_ 1784648388682186752
author Tu, Bin
Wang, Huiyuan
An, Xinran
Qu, Jingkun
Li, Qianqian
Gao, Yanrong
Shi, Mingjie
Qiu, Hong
Huang, Yongzhuo
author_facet Tu, Bin
Wang, Huiyuan
An, Xinran
Qu, Jingkun
Li, Qianqian
Gao, Yanrong
Shi, Mingjie
Qiu, Hong
Huang, Yongzhuo
author_sort Tu, Bin
collection PubMed
description The heparin polysaccharide nanoparticles block the interaction between heparan sulfate/S protein and inhibit the infection of both wild-type SARS-CoV-2 pseudovirus and the mutated strains through pulmonary delivery. [Figure: see text]
format Online
Article
Text
id pubmed-8830937
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88309372022-02-11 Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants Tu, Bin Wang, Huiyuan An, Xinran Qu, Jingkun Li, Qianqian Gao, Yanrong Shi, Mingjie Qiu, Hong Huang, Yongzhuo Acta Pharm Sin B Letter to the Editor The heparin polysaccharide nanoparticles block the interaction between heparan sulfate/S protein and inhibit the infection of both wild-type SARS-CoV-2 pseudovirus and the mutated strains through pulmonary delivery. [Figure: see text] Elsevier 2022-07 2022-02-11 /pmc/articles/PMC8830937/ /pubmed/35169535 http://dx.doi.org/10.1016/j.apsb.2022.01.019 Text en © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter to the Editor
Tu, Bin
Wang, Huiyuan
An, Xinran
Qu, Jingkun
Li, Qianqian
Gao, Yanrong
Shi, Mingjie
Qiu, Hong
Huang, Yongzhuo
Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
title Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
title_full Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
title_fullStr Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
title_full_unstemmed Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
title_short Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
title_sort inhaled heparin polysaccharide nanodecoy against sars-cov-2 and variants
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830937/
https://www.ncbi.nlm.nih.gov/pubmed/35169535
http://dx.doi.org/10.1016/j.apsb.2022.01.019
work_keys_str_mv AT tubin inhaledheparinpolysaccharidenanodecoyagainstsarscov2andvariants
AT wanghuiyuan inhaledheparinpolysaccharidenanodecoyagainstsarscov2andvariants
AT anxinran inhaledheparinpolysaccharidenanodecoyagainstsarscov2andvariants
AT qujingkun inhaledheparinpolysaccharidenanodecoyagainstsarscov2andvariants
AT liqianqian inhaledheparinpolysaccharidenanodecoyagainstsarscov2andvariants
AT gaoyanrong inhaledheparinpolysaccharidenanodecoyagainstsarscov2andvariants
AT shimingjie inhaledheparinpolysaccharidenanodecoyagainstsarscov2andvariants
AT qiuhong inhaledheparinpolysaccharidenanodecoyagainstsarscov2andvariants
AT huangyongzhuo inhaledheparinpolysaccharidenanodecoyagainstsarscov2andvariants

Ejemplares similares